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Abstract 
Purpose: There are limited data to evaluate the impact of ambulatory clinical pharmacist recommendations on family medicine resident 
prescribing and monitoring of medications. The purpose of this study is to begin to gain insight in this area by answering the research 
question, “How many ambulatory clinical pharmacist recommendations for drug therapy problem (DTP) resolution are implemented 
on the day of a medication therapy management (MTM) visit in an outpatient family medicine residency clinic?” 
Methods: This is a retrospective chart review of face-to-face MTM encounters conducted by ambulatory clinical pharmacists (including 
pharmacist residents) from August 1, 2012 to June 30, 2015 at a family medicine residency clinic. Descriptive statistics were conducted 
to both quantify the number of DTPs identified and resolved on the day of the MTM visit as well as categorize the DTPs. 
Results: Based on the 728 MTM encounters analyzed, patients were an average of 53.6 years old and took 11.9 medications to treat 
5.7 medical conditions. A total of 3057 DTPs were identified in the 728 encounters, of which 1303 were resolved the same day as the 
MTM visit. This resulted in an average of 4.2 DTPs identified and 2.0 resolved per visit per patient. The most common DTP category 
identified in this study was the need for additional drug therapy (41.6%). 
Conclusions: Approximately half of the ambulatory clinical pharmacist’s DTP resolution recommendations were implemented the same 
day they were identified, which highlights the strength of team-based patient care and interprofessional collaboration in a residency 
teaching clinic. 
 
Key points: Clinical pharmacists serve as important team members in a variety of settings, including family medicine teaching clinics, 
where they can identify and help to resolve drug therapy problems discovered within patients’ medication regimens. This retrospective 
chart review of face-to-face medication therapy management encounters conducted in a family medicine teaching clinic identified 
that almost 50% of the drug therapy problems identified by a pharmacist were resolved on the same day through team-based care. 
The most common drug therapy category in this review was the need for additional drug therapy.  
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Introduction 
Medications continue to be a primary treatment modality for the 
management of acute and chronic diseases.1 Their prevalence of 
use is accompanied by significant expense to patients and the 
health care system.2 Even more concerning is the potential for 
medication-related problems to cause morbidity and mortality.3-
6 Pharmacists are increasingly being integrated as key members 
of the health care team, especially in primary care practices.7 
Pharmacists’ ability to assist in optimizing medications has 
demonstrated improvements in clinical, humanistic, and 
economic outcomes.8,9,10,11 Pharmacists improve patient 
outcomes in primary care through comprehensive medication 
management following a structured patient care process where 
each medication is evaluated for appropriateness, effectiveness,  
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safety, and the patient’s ability to take the medication as 
intended.12,13 Family medicine residency programs have 
incorporated clinical pharmacists into their practices.14 Clinical 
pharmacists can serve as both patient care providers and faculty 
preceptors to guide the Family Medicine Residents’ (FMRs) 
proficiency in medication management through a team-based 
approach to patient-centered care.15 Currently, there are several 
studies published about implementation of ambulatory clinical 
pharmacists’ recommendations for drug therapy problem 
resolution in ambulatory primary care clinics and community 
pharmacies9,16-19 but there is limited information published 
within the family medicine residency clinic environment.14,15 The 
purpose of this study is to evaluate how many ambulatory clinical 
pharmacist recommendations for drug therapy problem 
resolution are implemented on the day of a medication therapy 
management (MTM) visit in an outpatient family medicine 
residency clinic. 
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Methods 
Setting 
The Duluth Family Medicine Clinic (DFMC) is a residency teaching 
clinic located in Duluth, Minnesota.20 The family medicine 
residency program21 focuses on developing and preparing 
collaborative, rural-ready, full-spectrum family medicine 
physicians and includes 27 family medicine residents (8-10 FMRs 
per postgraduate year) under the preceptorship of eight family 
medicine faculty, one to two behavioral health faculty and two 
ambulatory clinical pharmacist faculty. The care team also 
includes two to three rotating ambulatory clinical pharmacist 
residents, nurses, medical assistants, and other clinic staff. 
During their residency, the FMRs have progressively more time 
in the clinic, ranging from two to four half-days per week, and 
they see an average of six patients per half-day.  
 
Clinical pharmacy services were introduced to the clinic in August 
of 2012. Pharmacists at this clinic provide comprehensive 
medication management in accordance with the process 
endorsed by the Patient-Centered Primary Care Collaborative 
and Joint Commission of Pharmacy Practitioners.12,13 This 
structured patient care process includes collecting information, 
assessing all drug therapies for indication, effectiveness, safety, 
and adherence, creating and implementing a plan, and following 
up. Patients are recruited by phone for face-to-face MTM visits 
by clinic staff based on acuity (e.g., recent hospitalization), 
complexity (e.g., multiple medications, multiple comorbidities), 
and clinical status (e.g., uncontrolled diabetes). MTM visits are 
typically conducted immediately prior to patients’ scheduled 
FMR visits. Upon completion of the MTM visit, the ambulatory 
clinical pharmacist provides verbal recommendations to the FMR 
regarding how to optimize the patient’s medication regimen; the 
FMR then implements recommendations they feel are 
appropriate and feasible for the day of visit; this may occur with 
or without precepting with a supervising physician depending on 
level of training and payer requirements. The ambulatory clinical 
pharmacist and FMR document their encounters with the patient 
in the electronic health record (EHR) as separate encounters. 
Drug therapy problems (DTPs) are tracked within the 
pharmacist’s documentation and categorized according to The 
Patient-Centered Approach to Medication Management.22 
 
Study Design 
This was a retrospective chart review of face-to-face MTM 
encounters conducted by ambulatory clinical pharmacists or 
pharmacist residents under preceptorship. All documented face-
to-face MTM encounters from August 1, 2012 to June 30, 2015 
were included. MTM encounters were excluded if the patient 
was under the care of family medicine faculty instead of a FMR. 
The following data were extracted from the EHR and compiled 
into a database: date of MTM visit, patient age, primary FMR 
physician, number of medical conditions, number of 
medications, number and category of drug therapy problems 
identified, and number of drug therapy problems resolved the 
same day as the MTM encounter. Descriptive statistics were 
conducted for analysis. Additionally, a preliminary analysis was 
conducted towards the end of the date range that explored the 
percentage of DTPs resolved the same day of the MTM visit that 
specifically correlated with the chief reason for the patient’s visit 
with the FMR. The purpose of this expanded analysis was to 
investigate whether there would be a higher percentage of DTPs 
resolved the same day of the MTM visit if the DTPs correlated 
with the chief reason for the patient’s visit with the FMR. This 
study was determined to be exempt from review by both the 
Essentia Health and University of Minnesota Institutional Review 
Boards. 
 
Results 
A total of 733 face-to-face MTM encounters (689 unique 
patients) were conducted at DFMC from August 1, 2012 to June 
30, 2015; five were excluded because the patient was not under 
the care of a FMR, which left 728 encounters for analysis. Table 
1 describes mean and median age and number of medical 
conditions and medications in the population.  
 
A total of 3057 drug therapy problems (DTPs) were identified in 
those 728 encounters of which 1303 were resolved the same day 
as the MTM visit. (Table 2) A preliminary analysis of the 
percentage of DTPs resolved the same day of the MTM visit that 
correlated with the chief reason for the patient’s visit with the 
FMR revealed that 63% were resolved the same day of the visit 
(N=185). 
 
The most common DTP category identified in this study was the 
need for additional drug therapy (41.6%), followed by the need 
for additional monitoring (14.5%), suboptimal adherence (9.9%) 
dose too low (9.4%), adverse drug reaction (7.3%), unnecessary 
therapy (6.7%), ineffective drug therapy (5.5%), and dose too 
high (5.1%) (see Table 3). 
 
Discussion 
The complexity of patients seen at DFMC for MTM visits can be 
represented by their average number of medical conditions (5.7) 
and medications (11.9). This complexity was similar to or slightly 
higher than “thousands of patient encounters from many 
different practices and settings” who had an average of 6 medical 
conditions and 9 medications, as reported by Cipolle et al.22  
 
Ambulatory clinical pharmacists identified an average of 4.2 DTPs 
on the day of the MTM visit, which was more than the 3.2 DTPs 
per visit detected by Czycalla et al. in a similar practice setting; 
their data was collected from four family medicine teaching 
clinics in Minnesota over the course of five months with a sample 
size of 541 MTM visits.23 The average number of DTPs identified 
at DFMC is also larger than data from primary care clinics with a 
group of non-resident physicians. Oliveira et al. identified a mean 
of 4.26 DTPs per patient, which translated to 1.15 DTPs per 
encounter as the 9,068 patients analyzed over the 10-year period 
were seen for an average of 3.7 encounters in that timeframe.18 
One explanation for the higher number of DTPs identified per 
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visit at DFMC may be that the majority of patients seen for MTM 
visits at DFMC were only seen for an initial visit, and that the 
mean DTPs per visit would be anticipated to decrease over time 
with subsequent MTM visits. Isetts et al. demonstrated a mean 
of 2.24 DTPs per patient, but this 1-year study focused on 
patients with hypertension or hyperlipidemia, so may not have 
reflected as comprehensive of a patient panel.9 Finally, data from 
MTM visits conducted in community settings revealed anywhere 
from 4.3 to 5.9 DTPs per patient, but these data are difficult to 
compare to the DFMC data owing to a difference in practice 
setting.16,17,19 Additionally, comparison is difficult due to lack of a 
consistent comprehensive care approach and differing patient 
care processes. As examples, Doucette 2003 solely focused on 
patients with hyperlipidemia, Doucette 2005 focused on a single 
payer (Medicaid), and recommendations were communicated in 
different ways (e.g., via patient or written to primary care 
provider).16,17,19 
 
Approximately half of the ambulatory clinical pharmacist’s DTP 
resolution recommendations were implemented the same day 
they were identified. The fact that not all DTP resolution 
recommendations were implemented the same day is not 
necessarily surprising because the clinical pharmacist’s process 
of care for a majority of visits is comprehensive to include 
assessment of appropriate indication, effectiveness, safety, and 
the ability of a patient to take the entirety of their medication 
therapies (prescription, OTC, supplements) as intended across all 
of their medical conditions. This comprehensive approach to 
each patient is in contrast to the majority of FMR visits with 
patients that are typically more focused on specific condition(s) 
or a chief concern whereby FMRs may need to prioritize the 
patient’s presenting concern and limit the number of additional 
items addressed with a patient in a visit for a variety of reasons 
(e.g., acuity, time constraints, patient health literacy, and 
resident’s skill level). Indeed, the preliminary analysis did 
uncover there was a higher percentage of DTPs resolved the 
same day of the MTM visit when the DTP correlated with the 
chief reason for the patient’s visit with the FMR.  
 
The most common DTP categories identified in this study were 
the need for additional drug therapy, followed by the need for 
additional monitoring, suboptimal adherence, and dose too low. 
With the exception of the need for additional monitoring (which 
was not categorized by Cipolle et al. nor noted by Oliveira et al.), 
these data align with the most commonly reported DTP 
categories in other comprehensive practices that follow similar 
DTP nomenclature and prioritization (e.g., need for additional 
drug therapy and dosage too low).18, 22 The most common DTP 
categories identified in the community setting differed slightly to 
include adverse drug reaction, ineffective drug therapy, the need 
for additional drug therapy, and adherence.16,17,19 Perhaps this is 
due to different information being available to the pharmacist 
conducting a visit in an external location. 
 
 
Strengths 
This study provides insight into the frequency of DTP resolution 
recommendations implemented as well as types of DTPs 
identified by pharmacists specifically in a family medicine 
residency clinic, an area of research not previously represented 
in the literature. An additional strength is that this study 
evaluated all of the MTM visits during the study period, not just 
a sample. 
 
Limitations 
There are several limitations to this study. The EHR data capture 
was limited to discrete data, which prevented obtainment of 
subcategory types of DTPs resolved day of visit, DTP specifics 
related to medications/conditions, DTPs resolved directly with 
patient (not through FMR), the categorization of DTPs not 
implemented, reasons why DTP recommendations were not 
implemented, and if DTP resolutions were implemented 
subsequent to day of visit. Additionally, the outcome of the DTP 
resolution is unknown. Finally, this study was conducted at only 
one clinic site, limiting its generalizability. 
 
Future Research 
Future research directed at identifying additional details about 
the DTPs identified would be valuable. For example, it would be 
useful to identify the subcategory types of DTPs and correlate 
DTPs with their respective medication/class and medical 
condition. It may also be helpful to identify if the “needs 
additional monitoring” category is linked to monitoring to 
determine either effectiveness or safety of the medication. This 
information would be beneficial in order to identify potential 
system improvements and/or gaps in FMR pharmacotherapy 
knowledge that could be addressed through systems change 
and/or additional FMR education/training. It would be useful to 
know more about how and when the DTP resolutions are 
implemented. In some cases, the plan for resolving DTPs can be 
implemented directly between the pharmacist and the patient 
during the visit (e.g., if it relates to an over-the-counter 
medication or adherence to a prescribed medication, or the 
pharmacist is working under a collaborative practice agreement 
allowing them to initiate, adjust, and discontinue prescription 
medications) while other interventions would require 
involvement of an FMR to adjust a prescription. Of note, the 
decision about whether or not to utilize a collaborative practice 
agreement in a residency teaching clinic may be deferred in order 
to use the recommendations as a teaching tool. It would be 
valuable to analyze the number, type, and timing of DTP 
resolutions that occur after the day of the MTM visit, categorize 
and appreciate reasons for recommendations that were not 
implemented, and evaluate implementation rates per residency 
year. Ultimately, it would be important to examine clinical and 
humanistic outcomes of the recommendations. Overall, this 
project has accelerated our understanding of the strengths and 
weaknesses of our EHR data capture methods and facilitated 
changes to allow for evaluation of the future research directions 
aforementioned.  
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Conclusion 
Clinical pharmacists serve as important team members in a 
variety of settings, including family medicine teaching clinics, 
where they can identify and help to resolve drug therapy 
problems discovered within patients’ medication regimens. 
These data highlight the strength of interprofessional 
collaboration in a residency teaching clinic. 
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Table 1. Patient Data 
 Age  
(n=728 encounters) 
Medical Conditions  
(n=726 encounters)a 
Medications  
(n=726 encounters)a 
Mean (SDb) 53.6 (+/-15.7) 5.7 (+/-2.5) 11.9 (+/-5.8) 
Median 55 5 11 
aData missing from electronic health record (i.e. information was not documented in visit note and  
couldn’t be extracted). Missing data not included in denominator for mean/median. 
bSD = Standard Deviation 
 
 
 
 
Table 2. Medication Therapy Management Visit Data 
 Drug Therapy Problems  
Identified Day of Visit  
(n=726 encounters)a 
Drug Therapy Problems  
Resolved Day of Visit  
(n=642 encounters)a 
Face-to-Face  
MTM Visit Time  
(n=724 encounters)a 
Mean (SDb) 4.2 (+/- 2.1) 2.0 (+/-1.7) 31.2 (+/-9.3) 
Median 4 2 30 
aData missing from electronic health record (i.e. information was not documented in visit  
note and couldn’t be extracted). Missing data not included in denominator for mean/median.  
bSD = Standard Deviation 
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Table 3. Drug Therapy Problem Category Results 
 
Table 3. Drug Therapy Problem (DTP) Category Results (n = 3,010a DTPs) 
INDICATION 48.3 (1,453/3,010), % (no.) 
Unnecessary Drug Therapy 
• Duplicate therapy 
• No medical indication at this time 
• Non-drug therapy more appropriate 
• Addiction/recreational drug use 
• Treating avoidable adverse reaction 
 
 
 
 
6.7 (202/3,010) 
Needs Additional Drug Therapy 
• Preventive therapy 
• Untreated condition 
• Synergistic therapy 
 
 
41.6 (1,251/3,010) 
EFFECTIVENESS – 14.9 (447/3,010) - excludes monitoring, % (no.)b 
Ineffective Drug 
• More effective drug available 
• Condition refractory to drug 
• Dosage form inappropriate 
• Contraindications present 
• Drug not effective for condition 
 
 
 
5.5 (165/3,010) 
Dosage Too Low, no. (%) 
• Dose too low 
• Frequency inappropriate 
• Incorrect administration 
• Drug interaction 
• Incorrect storage 
• Duration inappropriate 
 
 
 
 
9.4 (282/3,010) 
Needs Additional Monitoring, no. (%)a 
• Medication requires monitoring 
 
14.5 (438/3,010) 
SAFETY – 12.4 (374/3,010) - excludes monitoring, % (no.)b 
Adverse Drug Reaction 
• Undesirable effect 
• Unsafe drug for the patient 
• Drug interaction 
• Incorrect administration 
• Allergic reaction 
• Dosage increase/decrease too fast 
 
 
 
 
7.3 (220/3,010) 
 
Dosage Too High 
• Dose too high 
• Frequency inappropriate 
• Duration inappropriate 
• Drug interaction 
 
 
 
5.1 (154/3,010) 
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Needs Additional Monitoringb 
Medication requires monitoring 
 
14.5 (438/3,010) 
ADHERENCE 9.9 (298/3,010), % (no.)  
Adherence 
• Does not understand instructions 
• More cost-effective drug available 
• Cannot afford drug product 
• Patient prefers not to take 
• Patient forgets to take 
• Drug product not available 
• Cannot swallow/administer drug 
 
 
 
 
 
 
9.9 (298/3,010) 
a3,010/3,057 (98.5%) of DTPs were documented such that category could be extracted from electronic health record  
and included in this analysis. 
bThis analysis was unable to attribute “Needs Additional Monitoring” to either Effectiveness or Safety due to the limitations 
of the EHR documentation template during the time frame of this analysis. 
Adapted from Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice: The Patient-Centered Approach to 
Medication Management. 3rd ed. New York, NY: McGraw-Hill; 2012, p 157). 
 
 
